Joshua Reuss
@Joshua_Reuss
Thoracic Medical Oncologist @lombardicancer, Assistant Professor @Georgetown. Interested in immunotherapy translational clinical trials. Opinions are my own.
ID:1265707067098177539
27-05-2020 18:11:02
947 Tweets
1,8K Followers
370 Following
Follow People
Stephen V Liu, MD
Director of Thoracic Oncology & Developmental Therapeutics @Georgetown @LombardiCancer; Host @IASLC Podcast; Chair #TexasLung24 #PLCCLive24 #DCLung24 #HereWeGo
Jarushka Naidoo
Professor of Medical Oncology @CancerCentreIre | Thoracic Oncologist | Immunotherapy & Immune toxicity | Adjunct faculty Johns Hopkins University
Balazs Halmos
Thoracic/precision oncology 🇭🇺🇺🇸
Vivek Subbiah, MD
Chief, Early-Phase Drug Development|@SarahCannonDocs #Oncologist, #Phase1trials, #PrecisionMedicine. Tweets=My own.
Mark Lewis
Director, GI Oncology, @Intermountain. Interests: neuroendocrine tumors, cancer syndromes, empathy (even had a Whipple myself). Tweets my own.
#TexasLung24 Xiuning Le MD PhD MD Anderson Cancer Center goes deeper discussing 1st line line +EGFR treatment options and how to intensify treatment - how? for which pts and when?
➡️Flaura2: +chemo
➡️RAMOSE: +anti-vegf
➡️MARIPOSA: +antiegfr/met
➡️NORTHSTAR: +radiation
EGFR Resisters
#lcsm
Connection is empowering for patients. Many patient advocacy groups dedicated to lung cancer now offer connections, knowledge, and empowerment. Great talk by TerriConneran. #TexasLung24
A candid discussion on partnering with patient advocates from TerriConneran and KRASKickers - connect with these groups, empower patients. We’re in this together! #TexasLung24
.TerriConneran brings the patient voice to #TexasLung24 with a powerful talk. We all need to connect with patients and Advocacy groups such as KRASKickers to create change together!
Dr. Narjust Florez, MD, FASCO with an impt talk on integration of social media with oncology at #TexasLung24 . We are all online, why not harness it as a tool for change, collaboration and growth?
TTF in NSCLC. Dr. Joshua Sabari, MD attempts to unpack this intriguing therapy and dissect the LUNAR study results and other TTF studies at #TexasLung24 . Interpretation challenging in setting of evolving standard of care but confirmatory studies are ongoing
How will AI integrate into the clinic and patient care? Dr. Sandip Patel MD with an intriguing discussion of how this may be possible at #TexasLung24 from scan interpretation to finding appropriate clinical trials to EMR communications!
Dr. Paul Paik takes us through a tour of MET-altered NSCLC at #TexasLung24 including the biology of MET TKI-driven toxicities. Edema appears driven by VEGF. Perhaps ripe for an IIT?
#TexasLung24 If this panel of 🤩 experts on targeted therapies for advanced #lungcancer was a band, it will be the equivalent of the Beatles coming to Texas to play ACL Live
IASLC #lcsm
Christine Lovly, MD, PhD I.DagogoJackMD Jonathan Riess, MD MS Drs Paul Paik, Dr John Heymach, Mark Socinski
Resistance to EGFR TKIs is being further unraveled, and emerging resistance mechanisms include APOBEC mutagenesis, HIPPO-YAP pathway.
Rationale combination approaches, ADCs (HER3, Trop-2) may overcome resistance. Novel IO (e.g. ivonescimab) also being tested.
TLC Conference
Dr. Mark Socinski discusses mgmt of HER2m NSCLC at #TexasLung24 . T-DXd has transformed this space and many promising TKIs are in development.
Dr. Jonathan Riess, MD MS with an excellent discussion of the diverse resistance pathways to TKI therapy in EGFRm NSCLC at #TexasLung24 . Resistance-driven and resistance agnostic approaches will hopefully both have a future role.
Dr. John Heymach dissects the biology of unique EGFR mutations and how this influences therapeutic efficacy at #TexasLung24 . Fascinating to see how the science translates to the clinic!
Dr. Xiuning Le MD PhD examines novel Frontline strategies in EGFRm NSCLC at #TexasLung24 . Several factors in play here and hopefully we will soon have a more diverse array of options guided by pt-specific features.
Dr. Rachel E. Sanborn, MD discusses the rapidly evolving landscape of 1st line Rx for EGFRm NSCLC at #TexasLung24 . This is increasingly complex. Gone are days of osimertinib monotherapy for all. Tumor-specific factors and patient goals are key and shared-decision making will be key
No one better to discuss biomarker testing at #TexasLung24 than Dr. Christine Lovly, MD, PhD. Important points on harmonization, streamlining, and better reporting of results. TLC Conference
Always a treat to sit and learn from Dr. Christine Lovly, MD, PhD, today speaking on NGS testing in lung cancer at #TexasLung24 . Can't overstate the importance of this. Needs to be 100% use across stages to provide optimal care.
All star panel discussing #SCLC , mesothelioma, thymic cancers at #TexasLung24 with Drs. Davey Daniel, Quynh Nguyen, Lauren Averett Byers, MD, Misty Dawn Shields, Carl Gay, Melina Marmarelis, Chul Kim, and Jason Porter!
Expert presentation at #TexasLung24 on thymic malignancies from Dr. Chul Kim - while rare, there have been important data on novel systemic approaches. Looking forward to results from the ongoing sacituzumab govitecan study led by Drs. Kim and Jennifer Marks, MD
